M. Hall

发表

Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane

H. Gabra, P. Vasey, S. Kaye, 2013 .

p27 Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803

M. Loda, C. Compton, S. Jewell, 2011 .

Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581.

S. Jewell, M. Bertagnolli, R. Goldberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety results from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or type II/III oesophagogastric junction (OGJ) adenocarcinoma.

D. Smith, D. Cunningham, W. Allum, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ- confined node-negative urothelial bladder cancer (UBC).

S. Groshen, R. Cote, L. Klotz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.

D. Smith, A. Wotherspoon, D. Cunningham, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

C. Compton, S. Jewell, M. Bertagnolli, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803

M. Loda, C. Compton, S. Jewell, 2009, Clinical Cancer Research.

p 27 Kip 1 in Stage IIIColon Cancer : Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group BProtocol 89803

C. Compton, S. Jewell, M. Bertagnolli, 2009 .

Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.

J. Reis-Filho, D. Smith, M. Band, 2013, European journal of cancer.

Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.

D. Smith, D. Cunningham, W. Allum, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

R. Coombes, M. Climent, U. Dafni, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

V. Gebski, P. Gibbs, F. Lammert, 2017, The Lancet. Oncology.

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

T. Hickish, N. Heaton, O. Garden, 2020, The Lancet. Oncology.

A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).

R. Schilsky, R. Goldberg, G. Abou-Alfa, 2010, The oncologist.

p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803

M. Loda, C. Compton, S. Jewell, 2009, Clinical Cancer Research.